Devastating NMOSD attacks often lead to permanent disability1,2

Without proper treatment, patients remain vulnerable to repeat attacks3

Following any NMOSD attack…
Lightning bolt icon

67% of patients with optic neuritis had partial or no recovery4

Disability as a result of NMOSD icon

83% of patients with transverse myelitis had partial or no recovery4

At 1 year

Lightning bolt with a plus sign icon

If left untreated, 60% of patients will have a repeat attack3

At 3 years

NMOSD relapse icon

If left untreated, 90% of patients will have a repeat attack3

At 5 years

Blindness icon

4 out of 10 patients may be legally blind in at least 1 eye5

Walking impairment icon

2 out of 10 patients may require a walker5

Without treatment, NMOSD has a mortality rate of 22% to 30% at 5 years.6
With treatment, mortality declines to ~5%.6

Life expectancy for patients with NMOSD can be affected by several factors7-9:

  • Age at diagnosis
  • Attack recovery
  • Frequency of recurrent attacks
  • Race

Learn about an
NMOSD treatment option

Review diagnostic criteria Diagnostic Criteria

  1. Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018;384:96-103.
  2. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:1-15. doi:10.3389/fneur.2018.00888
  3. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107-1114.
  4. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(14):1-17.
  5. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81:1197-1204.
  6. Wallach AI, Tremblay M, Kister I. Advances in the treatment of neuromyelitis optica spectrum disorder. Neurol Clin. 2021;39:35-49.
  7. Mealy MA, Kessler RA, Rimler Z, et al. Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm. 2018;5:1-4. doi:10.1212/NXI.0000000000000468
  8. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834-1849.
  9. Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2014:20(8):1086-1094. doi: 10.1177/1352458513515085